Export financials
iBio (IBIO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

iBio Cash Flow 2026-2010 | IBIO
Brief cash flow overview of iBio
Cash flows are assessed across five available annual periods spanning 2021 to 2025.
Operating cash flow is negative at -$15.3 million, leaving internal funding capacity weak.
Only 0 of five annual observations were positive, indicating weak repeatability.
Conclusion
Taken together, iBio's cash flow indicators point to increased dependence on reserves or outside financing.
Annual Cash Flow iBio
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-23.2 M | -15.3 M | -18.6 M | -30.4 M | -37.5 M | -30.1 M | -13.3 M | -14 M | -13.5 M | -13.2 M | - | - | - | -4.85 M | -6.01 M | -5.34 M | - |
Depreciation & Amortization |
558 K | 484 K | 638 K | 674 K | 2.28 M | 472 K | 282 K | 179 K | 1.37 M | 1.33 M | 577 K | 5 K | 3 K | 2 K | 330 K | 377 K | - |
Accounts Payables |
4.42 M | 2.19 M | 358 K | 1.85 M | 4.26 M | 2.25 M | 1.76 M | 1 M | 790 K | 749 K | 1.18 M | 1.1 M | 297 K | 2.4 M | 2.85 M | - | - |
Accounts Receivables |
- | - | - | - | 1 M | 426 K | 75 K | 97 K | 75 K | 175 K | 484 K | 445 K | 205 K | 1.01 M | 351 K | - | - |
Total Inventories |
- | - | - | - | 3.9 M | 27 K | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow iBio
| 2026-Q4 | 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | -17 M | -10.9 M | -5.66 M | - | -5.66 M | - | - | - | -3.72 M | - | - | - | -5.34 M | - | - | - | -14 M | -21.6 M | - | - | -9.35 M | -20 M | - | - | -7.07 M | -15.5 M | -7.07 M | - | -2.29 M | -5.69 M | -2.29 M | - | -778 K | -5.45 M | -778 K | - | -3.02 M | -6.6 M | -3.02 M | - | -2.27 M | - | - | - | - | - | - | - | - | - | - | - | -911 K | 2.2 M | - | - | -1.29 M | -2.69 M | -1.29 M | - | -1.23 M | -2.01 M | -1.23 M |
Depreciation & Amortization |
- | 411 K | 264 K | 123 K | 5 K | 123 K | - | 5 K | 5 K | 120 K | - | 5 K | 5 K | 165 K | - | 5 K | 49 K | 271 K | 388 K | 122 K | 123 K | 306 K | 823 K | 119 K | 114 K | 97 K | 114 K | 97 K | 71 K | 66 K | 137 K | 66 K | 179 K | 179 K | 179 K | 360 K | 341 K | 338 K | 340 K | 338 K | 326 K | 324 K | 326 K | 324 K | 1 K | 1 K | 2 K | 1 K | 90 K | 1 K | 2 K | 1 K | 88 K | 1 K | 1 K | 1 K | 83 K | 82.4 K | 166 K | 82 K | 80 K | 80 K | 161 K | 80 K |
Accounts Payables |
2.19 M | 3.04 M | 2.65 M | 2.82 M | 2.65 M | 2.82 M | 2.19 M | 1.48 M | 614 K | 855 K | 358 K | 1.23 M | 1.86 M | 1.91 M | 1.85 M | 2.01 M | 4 M | 4.81 M | 4.26 M | 5.28 M | 2.74 M | 2.29 M | 2.25 M | 2.25 M | 2.41 M | 1.6 M | 1.76 M | 1.76 M | 442 K | 661 K | 1 M | 1 M | 662 K | 692 K | 790 K | 790 K | 701 K | 596 K | 749 K | 749 K | 731 K | 979 K | 1.18 M | 1.18 M | 1.33 M | 1.27 M | 1.1 M | 1.1 M | 984 K | 516 K | 297 K | 297 K | 1.24 M | 1.31 M | 2.4 M | 2.4 M | 2.71 M | 2.42 M | 2.85 M | 2.85 M | 4.04 M | 2.98 M | 2.9 M | 2.9 M |
Accounts Receivables |
- | - | - | 65 K | - | 65 K | - | - | - | - | - | - | - | - | - | 70 K | 970 K | 1.06 M | 1 M | 1 M | 111 K | 207 K | 426 K | 426 K | 180 K | 300 K | 75 K | 75 K | 224 K | 75 K | 97 K | 97 K | 155 K | 119 K | 75 K | 75 K | 136 K | 260 K | 175 K | 175 K | 25 K | 170 K | 484 K | 484 K | 202 K | 480 K | 445 K | 445 K | 584 K | - | 205 K | 205 K | 1.01 M | 1.01 M | 1.01 M | 1.01 M | 390 K | 390 K | 351 K | 351 K | 234 K | 320 K | 344 K | 344 K |
Total Inventories |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.28 M | 1.99 M | 587 K | 27 K | 27 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company iBio, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
ММЦБ
GEMA
|
- | - | - | ||
|
Lyra Therapeutics
LYRA
|
- | - | $ 24.9 M | ||
|
Промомед
PRMD
|
- | - | - | ||
|
Ionis Pharmaceuticals
IONS
|
$ 43.5 | 0.62 % | $ 6.96 B | ||
|
Agios Pharmaceuticals
AGIO
|
$ 31.25 | 0.88 % | $ 1.81 B | ||
|
Foghorn Therapeutics
FHTX
|
$ 2.0 | 0.74 % | $ 126 M | ||
|
Inhibikase Therapeutics
IKT
|
$ 2.0 | 0.5 % | $ 197 M | ||
|
Kamada Ltd.
KMDA
|
$ 8.0 | 1.34 % | $ 461 M | ||
|
Intellia Therapeutics
NTLA
|
$ 12.75 | 4.0 % | $ 1.38 B | ||
|
Ultragenyx Pharmaceutical
RARE
|
$ 14.5 | 3.19 % | $ 1.43 B | ||
|
Viridian Therapeutics
VRDN
|
$ 19.0 | 2.16 % | $ 1.93 B | ||
|
AbbVie
ABBV
|
$ 265.76 | 1.12 % | $ 470 B | ||
|
AbCellera Biologics
ABCL
|
$ 13.78 | 0.29 % | $ 4.12 B | ||
|
Abeona Therapeutics
ABEO
|
$ 5.11 | 1.59 % | $ 271 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
$ 4.67 | 4.94 % | $ 895 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
$ 20.11 | 0.8 % | $ 3.39 B | ||
|
Achieve Life Sciences
ACHV
|
$ 7.01 | 0.13 % | $ 306 M | ||
|
AC Immune SA
ACIU
|
$ 2.71 | 0.55 % | $ 273 M | ||
|
Aclaris Therapeutics
ACRS
|
$ 4.27 | 0.79 % | $ 523 M | ||
|
Adagene
ADAG
|
$ 2.8 | 0.28 % | $ 165 M | ||
|
ADC Therapeutics SA
ADCT
|
$ 1.23 | 8.85 % | $ 156 M | ||
|
Adial Pharmaceuticals
ADIL
|
$ 4.35 | 5.58 % | $ 2.91 M | ||
|
ADMA Biologics
ADMA
|
$ 10.11 | 4.01 % | $ 2.41 B | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
$ 29.84 | 5.26 % | $ 4.53 B | ||
|
Agenus
AGEN
|
$ 8.73 | 4.43 % | $ 260 M | ||
|
AIM ImmunoTech
AIM
|
$ 0.19 | 5.56 % | $ 308 K | ||
|
Akebia Therapeutics
AKBA
|
$ 0.91 | 5.26 % | $ 234 M | ||
|
Akari Therapeutics, Plc
AKTX
|
$ 8.76 | 0.46 % | $ 590 B | ||
|
Aldeyra Therapeutics
ALDX
|
$ 0.92 | 4.88 % | $ 55.3 M | ||
|
Alector
ALEC
|
$ 1.99 | 9.94 % | $ 205 M | ||
|
Aligos Therapeutics
ALGS
|
$ 5.4 | 0.36 % | $ 53.4 M | ||
|
Alkermes plc
ALKS
|
$ 42.76 | 2.42 % | $ 7.04 B | ||
|
Allogene Therapeutics
ALLO
|
$ 1.5 | 0.33 % | $ 331 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
$ 219.89 | 0.08 % | $ 28.8 B | ||
|
Altimmune
ALT
|
$ 2.67 | 0.36 % | $ 235 M | ||
|
ALX Oncology Holdings
ALXO
|
$ 1.21 | 1.23 % | $ 64.9 M | ||
|
Amgen
AMGN
|
$ 402.98 | 0.08 % | $ 217 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
$ 25.37 | 0.39 % | $ 1.19 B | ||
|
Amarin Corporation plc
AMRN
|
$ 12.09 | 0.31 % | $ 5.02 B | ||
|
Amneal Pharmaceuticals
AMRX
|
$ 20.35 | 0.25 % | $ 6.38 B | ||
|
AnaptysBio
ANAB
|
$ 49.2 | 1.38 % | $ 1.43 B | ||
|
Anika Therapeutics
ANIK
|
$ 19.73 | 3.3 % | $ 283 M | ||
|
ANI Pharmaceuticals
ANIP
|
$ 72.58 | 0.55 % | $ 1.46 B | ||
|
Annexon
ANNX
|
$ 4.2 | 0.24 % | $ 651 M | ||
|
Annovis Bio
ANVS
|
$ 1.2 | 1.69 % | $ 24.7 M | ||
|
Aprea Therapeutics
APRE
|
$ 0.68 | 0.16 % | $ 4.45 M |